Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-alcoholic steatohepatitis drugs

- PMLiVE

Allergan boosts migraine standing with $1bn acquisition

Acquires Californian neurology specialist MAP Pharmaceuticals

- PMLiVE

Allergan gets US approval for Botox in overactive bladder

Could add $200m to annual sales

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

- PMLiVE

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

- PMLiVE

Gilead posts strong data for all-oral hepatitis C treatment

Achieves sustained virologic response in 78 per cent of participants

- PMLiVE

Allergan to pay up to $375m for SkinMedica’s skincare business

Boosts aesthetic products division, which already includes Botox

- PMLiVE

Gilead advances HIV drug into phase III

The treatment is a chemical variant of Gilead's successful HIV drug Viread

Allergan signs $1.4bn eye drug deal with Molecular Partners

Will develop DARPin proteins to target AMD and other eye conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links